Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21730478 | 0.86 | LMNA (0.42) | LMNANPSR1SIGMAR1ALDH1A1ACKR3 | |
| SCHEMBL13681670 | 0.86 | NPSR1 (0.52) | LMNANPSR1KMT2AMEN1 | |
| SCHEMBL22332304 | 0.86 | ALDH1A1 (0.46) | NPSR1ALDH1A1ACKR3KMT2A | |
| SCHEMBL20061880 | 0.84 | EPHX1 (0.51) | NPSR1SIGMAR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL20061877 | 0.84 | KDM4E (0.45) | LMNANPSR1ALDH1A1KMT2AKDM4E | |
| SCHEMBL22332321 | 0.83 | NPSR1 (0.41) | LMNANPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL12101985 | 0.83 | NPSR1 (0.58) | NPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL15337701 | 0.81 | NPSR1 (0.66) | LMNANPSR1SIGMAR1ALDH1A1ACKR3 | |
| SCHEMBL12708609 | 0.81 | NPSR1 (0.66) | NPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL21730479 | 0.81 | L3MBTL1 (0.44) | LMNANPSR1SIGMAR1ALDH1A1ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | TPSD1, TPSAB1, TMSB4X | LMNA 284/4885NPSR1 1062/4885SIGMAR1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.